Carisma Therapeutics, Inc.CARMNASDAQ
Loading
Year-over-year book value per share growth
Latest
98.12%
↑ 127% vs avg
Percentile
P85
Within normal range
Streak
4 qtr
Consecutive growthAccelerating
Average
-361.66%
Historical baseline
| Period | Value |
|---|---|
| Q3 2025 | 98.12% |
| Q2 2025 | -25.43% |
| Q1 2025 | -30.37% |
| Q4 2024 | -151.38% |
| Q3 2024 | -3190.56% |
| Q2 2024 | -96.74% |
| Q1 2024 | -59.48% |
| Q4 2023 | -42.84% |
| Q3 2023 | -30.64% |
| Q2 2023 | -22.50% |
| Q1 2023 | 160.33% |
| Q4 2022 | -679.59% |
| Q3 2022 | -9738.71% |
| Q2 2022 | -100.03% |
| Q1 2022 | 0.63% |
| Q4 2021 | 5.21% |
| Q3 2021 | 190.82% |
| Q2 2021 | 376.63% |
| Q1 2021 | 175.41% |
| Q4 2020 | 44.26% |
| Q3 2020 | -501.44% |
| Q2 2020 | -113.89% |
| Q1 2020 | 169.10% |
| Q4 2019 | -1098.11% |
| Q3 2019 | -87.20% |
| Q2 2019 | -61.26% |
| Q1 2019 | -13.91% |
| Q4 2018 | -12.75% |
| Q3 2018 | -42.39% |
| Q2 2018 | 69.81% |
| Q1 2018 | 32.29% |
| Q4 2017 | -26.85% |
| Q3 2017 | -34.19% |
| Q2 2017 | -21.45% |
| Q1 2017 | -16.03% |
| Q4 2016 | -21.27% |
| Q3 2016 | 550.89% |
| Q2 2016 | -49.04% |
| Q1 2016 | -37.11% |
| Q4 2015 | -34.60% |